MEDFREE, INC.

Medtech · Private

Percutaneous catheter-based device for minimally invasive tricuspid valve repair via jugular vein access

Claim this profile

Follows are private to you and power your alerts

Updated · medfreeinc.com

Sector
Medtech
Total capital
$3M
Federal grants
$3M
6 awards · 2020–2024
Rank in peer group#424 of 538
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
2
8 pending · first 2021
Rank in peer group#190 of 538

Capital timeline

20202021202220232024FEDERAL ↑EQUITY ↓Cumulative $3M$299K$354K$55K$1.3M$652K$275K
20202021202220232024FEDERAL ↑EQUITY ↓Cumulative $3M$299K$354K$1.3M$652K

Latest events

  • Federal grantNSF · Phase I · SBIR Phase I: Novel Self-Closing, Transcatheter, Edge-to-Edge Repair Device to Percutaneously Treat Tricuspid Valve Regurgitation Using Jugular or Femoral Vein Access$275K
  • Federal grantHealth and Human S · Phase II · Mitral Valve Repair System to Percutaneously Treat Moderate to Severe Regurgitation Using Alfieri Edge-to-Edge Technique$652K
  • Federal grantHealth and Human S · Phase II · Mitral Valve Repair System to Percutaneously Treat Moderate to Severe Regurgitation Using Alfieri Edge-to-Edge Technique$1.3M
  • Federal grantHealth and Human S · Phase I · Mitral Valve Repair System to Percutaneously Treat Moderate to Severe Regurgitation Using Alfieri Edge-to-Edge Technique$55K
  • Federal grantHealth and Human S · Phase I · Mitral Valve Repair System to Percutaneously Treat Moderate to Severe Regurgitation Using Alfieri Edge-to-Edge Technique$354K
  • Federal grantHealth and Human S · Phase I · Mitral Valve Repair System to Percutaneously Treat Moderate to Severe Regurgitation Using Alfieri Edge-to-Edge Technique$299K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 538 peers

Line = median

Medtech · Device

  • Federal grantsBelow median
  • Granted patents#190 · top 35%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 2 granted of 10
  • PendingTissue Grasping Devices And Related MethodsUSPTOApplication 18433970
  • GrantedTissue Grasping Devices And Related MethodsUSPTOUS 11,723,769
  • PendingTissue Grasping Devices And Related MethodsUSPTOApplication 17497373
Show all 10 patent records
  • Tissue Grasping Devices And Related MethodsJan 2, 2025 · Application 18433970Pending
  • Tissue Grasping Devices And Related MethodsAug 15, 2023 · US 11,723,769Granted
  • Tissue Grasping Devices And Related MethodsJan 27, 2022 · Application 17497373Pending
  • Tissue Grasping Devices And Related MethodsNov 30, 2021 · US 11,185,413Granted
  • Tissue Grasping Devices And Related MethodsApplication PCTUS2019013853Pending
  • Tissue Grasping Devices And Related MethodsApplication 62617946Pending
  • Tissue Grasping Devices And Related MethodsApplication PCTUS2017042003Pending
  • Tissue Grasping Devices And Related MethodsApplication 18335736Pending
  • Tissue Grasping Devices And Related MethodsApplication 63051737Pending
  • Tissue Grasping Devices And Related MethodsApplication 62994575Pending

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .